. Initial antimicrobial therapy.
Background. Targeting "low-hanging fruit" is a pillar of antimicrobial stewardship (AMS). Β-lactam allergies (BLA) frequently restrict clinical decision-making and lead to utilization of alternative, less preferred antimicrobials making them an ideal AMS target. Prior studies have demonstrated that BLA are grossly over reported by patients. This study aimed to calculate the excess pharmaceutical expenditures incurred by utilization of aztreonam in patients who had previously (or subsequently) tolerated a β lactam (BL).
Methods. Retrospective chart review was performed on inpatients >18 years old at our institution who received at least one dose of aztreonam during the 2017 calendar year. Data collected included: BLA, both prior and subsequent BL classes tolerated, number of doses and days of aztreonam administered. Patients were excluded from the analysis if they did not have a documented BLA or if they received aztreonam as targeted/de-escalation therapy. Cost of aztreonam therapy was then compared with the cost of alterative BL agents based on prior and subsequently tolerated classes of BLs. Comparator agents included: pipericillin/tazobactam (penicillin), cefepime (cephalosporin) and meropenem (carbapenem). Wholesale acquisition costs were used for each agent and comparator regimens were based on our health system-wide dosing guidelines adjusted for renal function.
Results. One hundered thirty-two patients met inclusion criteria. Background. Given the severity of S. aureus bacteremia, prompt initiation of appropriate antibiotics is key. YNHH implemented the Cepheid ® Xpert MRSA/SA PCR in an effort to decrease the time needed to identify MRSA-B, MSSA-B, and CoNS. The impact of rapid diagnostics has been limited without stewardship or infectious disease involvement. Our unique notification algorithm utilized our on-call pharmacy residents to allow for 24/7 coverage. The primary objective was time to optimal antibiotic therapy (OAT) before and after implementation of the PCR and algorithm. Secondary outcomes included time to blood culture clearance (BCC), acceptance rate of pharmacist interventions, days of vancomycin therapy avoided, and 30-day mortality.
Methods. A retrospective cohort study was conducted in adult inpatients with blood cultures positive for Gram positive cocci in clusters. The pre-implementation, control group (CG) included patients from April 2017 to October 2017 and the post-implementation, intervention group (IG) was from October 2017 to April 2018. Patients <18 years and polymicrobial bacteremia were excluded. Data collected in addition to primary and secondary outcomes included baseline demographics, allergies and empiric antibiotics. OAT included vancomycin for MRSA-B or MSSA-B with severe β-lactam allergy; nafcillin or cefazolin for MSSA-B; and discontinuation of vancomycin for CoNS deemed a contaminant.
Results. Of the 544 patients reviewed, 434 met inclusion criteria: 182 in the CG and 252 in the IG with similar baseline characteristics. Mean time to OAT decreased from 10 hours in the CG to 5 hours in the IG (P = 0.006). Time to BCC in the CG and IG cohorts decreased from 100 to 43 hours (P = 0.0001). One day of vancomycin was avoided in patients with MSSA-B and 2 days with CoNS. 30-day mortality decreased from 18% (n = 32) in the CG vs. 6% (n = 15) in the IG (P = 0.0001). Finally, 95% (n = 153/161) of pharmacist interventions were accepted.
Conclusion. Utilizing the on-call pharmacy resident for notification of rapid diagnostic results for S. aureus bacteremia, we saw a significant decrease in time to OAT, BCC, and 30-day mortality. Our study demonstrates that in the setting of limited stewardship resources, additional members of the healthcare team can be used to optimize antibiotics in conjunction with rapid diagnostics.
Disclosures. All authors: No reported disclosures. Saturday, October 6, 2018: 12:30 PM Background. Since its introduction in 2009, use of daptomycin for treatment of enterococcal infections has resulted in the emergence of DNSE. Between 2009 and 2013, daptomycin nonsusceptibility among E. faecium was closely associated with emergence of a unique and dominant clone ST736 in our institution. In 2014, we instituted targeted measures to optimize the use of daptomycin. In this study, we describe the significant phenotypic and genotypic impact of reduced daptomycin use on clinical enterococcal isolates.
Phenotypic and Genotypic Impact of Antibiotic Stewardship Intervention on Daptomycin-Nonsusceptible Enterococcus faecium (DNSE) Clinical Isolates
Methods. Enterococcal clinical isolates were recovered from January 2014 through December 2017. Daptomycin susceptibility was determined by MicroScan WalkAway™ System and confirmed by E-test. Selected DNSE and vancomycin-resistant E. faecium (VREfm) clinical isolates were analyzed by next-generation sequencing (NGS) using the Illumina systems to provide multilocus sequencing type (MLST). Daptomycin utilization data were extracted from pharmacy records.
Results. Targeted antibiotic stewardship initiatives consisted of preapproval, daily review for optimization of dose and duration, rapid de-escalation, consideration for appropriate alternative antibiotics for select disease syndromes and stopping of inappropriate daptomycin therapy. Over 4 years, this lead to a 39% reduction in overall use of daptomycin. Besides direct cost saving, this reduced use was associated with significant reduction in daptomycin nonsusceptibility from 12% to 4%, lowering of MIC 90 from 8 to 4 μg/mL, and a clonal shift from dominant ST736 to ST117. 
